21:57 , May 10, 2019 |  BC Extra  |  Company News

May 10 Company Quick Takes: Red flags for Daiichi ahead of ODAC; plus JHL/Genentech, J&J, Gilead

FDA reviewers raise concerns about Daiichi’s quizartinib, pexidartinib  Despite both pexidartinib and quizartinib meeting the primary endpoints in their pivotal trials, FDA reviewers raised concerns about each agent from Daiichi Sankyo Co. Ltd. (Tokyo:4568) in...
18:09 , May 11, 2018 |  BC Week In Review  |  Company News

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced an Ebola virus outbreak in the...
23:04 , May 9, 2018 |  BC Extra  |  Politics & Policy

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced Tuesday an Ebola virus outbreak in...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

Ad26: Phase III started

Johnson & Johnson began the open-label, Sierra Leonean Phase III EBOVAC-Salone trial to evaluate 0.5 mL intramuscular Ad26.ZEBOV followed by 0.5 mL intramuscular MVA-BN Filo 2 months later in about 440 healthy volunteers. The first...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

MVA-BN Filo: Phase III started

Johnson & Johnson began the open-label, Sierra Leonean Phase III EBOVAC-Salone trial to evaluate 0.5 mL intramuscular Ad26.ZEBOV followed by 0.5 mL intramuscular MVA-BN Filo 2 months later in about 440 healthy volunteers. The first...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Ad26: Phase II started

Bavarian Nordic A/S (CSE:BAVA, Kvistgaard, Denmark) said the Oxford Vaccines Group of the University of Oxford (Oxford, U.K.) began a double-blind, U.K. and French Phase II trial to evaluate the company’s MVA-BN Filo vaccine and...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

MVA-BN Filo: Phase II started

Bavarian Nordic said the Oxford Vaccines Group of the University of Oxford (Oxford, U.K.) began a double-blind, U.K. and French Phase II trial to evaluate the company’s MVA-BN Filo vaccine and the Ad26.ZEBOV vaccine from...